NextCell Pharma AB (FRA:65G) Total Stockholders Equity: €4.65 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:65G NextCell Pharma AB FRA:65G
42 GF Score
Price €0.08
GF Value €0.06
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is NextCell Pharma AB Total Stockholders Equity?

NextCell Pharma AB FRA:65G +5.42% 42 Total Stockholders Equity is €4.65 Mil as of Dec. 2025. GuruFocus rates FRA:65G with a GF Score™ of 42/100 and a GF Value™ of €0.06 (Significantly Overvalued). The stock has 4 warning signs investors should review.

NextCell Pharma AB's Total Stockholders Equity for the quarter that ended in Dec. 2025 was €4.65 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. NextCell Pharma AB's Book Value per Share for the quarter that ended in Dec. 2025 was €0.04. The ratio of a company's debt over equity can be used to measure how leveraged this company is. NextCell Pharma AB's Debt-to-Equity for the quarter that ended in Dec. 2025 was 0.00.

NextCell Pharma AB  (FRA:65G) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

NextCell Pharma AB's Book Value per Share for the quarter that ended in Dec. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(4.65-0)/111.393
=0.04

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

NextCell Pharma AB's Debt-to-Equity for the quarter that ended in Dec. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 4.65
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NextCell Pharma AB Total Stockholders Equity Related Terms

NextCell Pharma AB Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for NextCell Pharma AB's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NextCell Pharma AB Total Stockholders Equity Chart

NextCell Pharma AB Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.70 10.99 6.41 5.90 5.95

NextCell Pharma AB Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Dec25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.14 4.57 3.77 5.95 4.65
FRA:65G
42GF Score
NextCell Pharma AB FRA:65G
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of €4.65 Mil mean?
NextCell Pharma AB (FRA:65G) has a Total Stockholders Equity of €4.65 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for NextCell Pharma AB and its competitors.
Is NextCell Pharma AB's Total Stockholders Equity too high?
NextCell Pharma AB's current Total Stockholders Equity is €4.65 Mil. Overall, NextCell Pharma AB has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NextCell Pharma AB's Total Stockholders Equity compare to VRTX and REGN?
NextCell Pharma AB's Total Stockholders Equity of €4.65 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for NextCell Pharma AB and its competitors. NextCell Pharma AB's current Total Stockholders Equity is €4.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NextCell Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, NextCell Pharma AB (FRA:65G) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.06, compared to a current price of €0.08 — trading 39.5% above its estimated fair value. The current Total Stockholders Equity is €4.65 Mil. NextCell Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For NextCell Pharma AB (FRA:65G), the current Total Stockholders Equity is €4.65 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NextCell Pharma AB (FRA:65G) Overvalued in 2026?

Based on GuruFocus' analysis, NextCell Pharma AB stock appears to be overvalued. The current stock price of €0.08 is trading 39.5% above its estimated GF Value™ of €0.06. GuruFocus considers NextCell Pharma AB to be Significantly Overvalued.

Key valuation signals for FRA:65G:

  • Total Stockholders Equity: €4.65 Mil
  • GF Value™: €0.06 vs. price of €0.08 (39.5% above fair value)
  • GF Score™: 42/100 with 4 warning signs

No single metric tells the full story. See the FRA:65G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NextCell Pharma AB Business Description

Other Exchanges NXTCL:Sweden
Address Karolinska Institutet Science Park, Halsovagen 7, Huddinge, SWE, 14157
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
42GF Score

Get the complete analysis for FRA:65G

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.08
Price
€0.06
GF Value